Bioterrorism And Gene Editing: Can Crispr Tool Be Used As Biological Weapon In War?
By Himanshu Goenka,
IB Times
| 12. 14. 2016
Crispr is a tool that allows for genes to be edited, and has great potential in the treatment of a wide range of diseases, including some for which there is currently no known cure. It rose to prominence in 2015, when it was chosen as the breakthrough technology of the year by the American Association for the Advancement of Science, and became even better known in 2016 when scientists behind it were strong contenders for the Nobel Prize (which it finally didn’t win) and also appeared in Time magazine’s readers’ poll for the Person of the Year title.
Even as a legal battle is currently underway for the patent rights to Crispr (its Cas9 variant, to be specific), the technology is far from perfect right now — scientists are still working on making it more precise and the first human test involving a gene modified using Crispr took place only in October. And yet, it has made it to the list put together by U.S. intelligence agencies on national security threats.
However, in a somewhat surprising announcement in February 2016...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...